Home›Trial›NCT07156149
NCT07156149Active, not recruiting

Fabhalta Capsules Specified Drug-use Survey

Study Summary

The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.

Conditions
C3 Glomerulopathy
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
NVS
Novartis AG
Diversified Pharma
C51/100
Study Details
Enrollment33 participants
Primary Completion2028-06-30
Lead SponsorNovartis Pharmaceuticals
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Primary completion: 2028-06-30
Enrolled: 33 participants
Sponsor Catalyst Profile

Novartis AG (NVS) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVS Full Pipeline →All Companies →
Other Trials from Novartis AG
NCT07206056An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tul…(PHASE1/PHASE2)NCT06905301Implementation Study to Describe and Compare Retention Rate and Adherence to Adj…NCT06799000A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Ad…(PHASE3)NCT05109728A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in C…(PHASE1)NCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Particip…(PHASE3)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence